Get the Stockscreener App
4.33
8.25%
0.33
Pre-market:
4.39
0.06
+1.39%
Rezolute Inc stock is traded at $4.33, with a volume of 2.40M.
It is up +8.25% in the last 24 hours and up +29.64% over the past month.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
See More
Previous Close:
$4.00
Open:
$4.262
24h Volume:
2.40M
Relative Volume:
1.11
Market Cap:
$416.95M
Revenue:
-
Net Income/Loss:
$-81.49M
P/E Ratio:
-5.3523
EPS:
-0.809
Net Cash Flow:
$-73.48M
1W Performance:
+6.13%
1M Performance:
+29.64%
6M Performance:
+165.64%
1Y Performance:
+3.10%
1-Day Range:
$4.262
$4.52
1-Week Range:
$3.705
$4.52
52-Week Range:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.33 | 416.95M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-11-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-11-25 | Downgrade | Craig Hallum | Buy → Hold |
| Dec-11-25 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
RZLT Maintained by Guggenheim -- Price Target Raised to $11.00 - GuruFocus
Guggenheim raises Rezolute stock price target on trial outlook - Investing.com UK
Guggenheim raises Rezolute stock price target on trial outlook By Investing.com - Investing.com Canada
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
RZLT stock on the move: What sparks the 38% jump in the past week? - MSN
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL) - The Globe and Mail
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance
RZLT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Cautious OutlookDiluted EPS Report - newsline.com
Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT) - The Globe and Mail
REZOLUTE INC (RZLT) Stock Chart - ChartMill
RZLT: Strong interim efficacy in tumor HI and key regulatory milestones expected later this year - TradingView
RZLT: Strong interim efficacy in tumor HI and regulatory clarity for congenital HI expected this year - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - The Globe and Mail
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society - The Manila Times
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism - Quiver Quantitative
Rezolute (RZLT) Receives a Buy from Guggenheim - The Globe and Mail
Phase 3 congenital hyperinsulinism study results to be shared at ENDO 2026 - Stock Titan
RZLT Maintained by Maxim Group -- Price Target Raised to $14.00 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Rezolute (RZLT) Gains on Upgrade Following Positive Trial Data - GuruFocus
Rezolute upgraded at Citizens after late-stage trial data for lead asset - Seeking Alpha
RZLT Maintained by Wedbush -- Price Target Raised to $6.00 - GuruFocus
RZLT Upgraded by Citizens -- Price Target Announced at $11.00 - GuruFocus
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute’s stock up on interim Phase III tumour HI data - Yahoo Finance
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data - Investing.com
Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating - marketscreener.com
Rezolute Price Target Raised to $6.00/Share From $5.00 by BTIG - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $14 - Moomoo
Rezolute (RZLT) Shares Rise on Positive Trial Update for Ersodet - GuruFocus
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study - Benzinga
RZLT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Rezolute rises after late-stage trial update (RZLT:NASDAQ) - Seeking Alpha
Rezolute Announces Positive Interim Phase 3 upLIFT Results for Ersodetug in Tumor Hyperinsulinism, Six of Eight Responders Achieved IV Glucose Discontinuation 1 - Minichart
Rezolute (RZLT) Shares Phase 3 Study Progress of Ersodetug in Tu - GuruFocus
Rezolute reports interim data from tumor hyperinsulinism trial By Investing.com - Investing.com South Africa
Rezolute Reports Positive Phase 3 Data for Ersodetug - TipRanks
Rezolute reports interim data from tumor hyperinsulinism trial - Investing.com
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - The Manila Times
Rezolute interim Phase 3 upLIFT data: 6 of 8 meet primary responder criterion; study 50% enrolled - TradingView
Rezolute (NASDAQ: RZLT) reports positive Phase 3 upLIFT tumor HI data - Stock Titan
Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial - marketscreener.com
Rezolute (RZLT) Q1 2026 Earnings: EPS Surpasses Estimates Amid Continued R&D ProgressEstimate Accuracy - The Legal Advocate
RZLT Q1 2026 Earnings: EPS Beat Expectations Despite Negative Stock ReactionEarnings Weakness Phase - newsline.com
Rezolute (RZLT) Edges Higher: Key Levels to Watch After 1.08% GainOutside Reversal - newsline.com
RZLT Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Pipeline AdvancesEarnings Momentum Score - newsline.com
Rezolute Inc. (RZLT) Slides Amid Sector Pressure: Key Levels to WatchBPI Reversal - newsline.com
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rezolute Inc Stock (RZLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):